Moderna’s mRNA-1010 flu vaccine, already under review in the EU, Canada, and Australia, has hit a snag in the US. The FDA has declined to review the vaccine, arguing that the comparator vaccine used in Moderna’s trials does not represent the “best-available standard of care,” a requirement not explicitly stated in FDA regulations or industry guidance, potentially slowing down the rollout of more effective flu vaccines in the United States. This decision raises questions about the FDA’s evaluation criteria and its impact on innovation in vaccine development.
Key Takeaways
- The FDA refused to review Moderna’s mRNA-1010 flu vaccine due to concerns over the comparator vaccine used in trials.
- Moderna CEO Stéphane Bancel expressed disappointment, stating that the decision doesn’t align with the goal of enhancing America’s leadership in innovative medicine.
- mRNA-1010 has been accepted for review in the European Union, Canada, and Australia, creating a regulatory divergence.
- Moderna is seeking a meeting with the FDA to understand the path forward for US approval.
Why Did the FDA Reject Moderna’s Application?
The core of the FDA’s rejection lies in its assessment of the comparator vaccine used in Moderna’s clinical trials for mRNA-1010. According to the FDA’s letter to Moderna, the agency did not consider the trial “adequate and well-controlled” because the comparator vaccine “does not reflect the best-available standard of care.” This decision has sparked debate, as neither FDA regulations nor its guidance to industry explicitly mandate the use of the “best-available standard of care” in comparator arms. Moderna CEO Stéphane Bancel criticized the FDA’s move, stating it “does not further our shared goal of enhancing America’s leadership in developing innovative medicines.” Bancel highlights the potential for hindering medical advancement if regulatory hurdles prioritize existing standards over the evaluation of novel approaches.
The FDA’s Center for Biologics Evaluation and Research (CBER) has not publicly commented beyond the letter. Moderna’s mRNA-1010 vaccine utilizes messenger RNA (mRNA) technology, a cutting-edge approach that has shown promise in various applications. However, potential concerns could revolve around demonstrating statistically significant improvements over existing vaccines to justify approval. The company has requested a meeting with the FDA to discuss the concerns and determine the necessary steps for US approval, particularly considering the vaccine’s acceptance for review in other major markets. “It is a balancing act, but the FDA needs to be open to innovation while maintaining safety,” notes Dr. Anna Kramer, a vaccine researcher at Johns Hopkins, in an interview with Bloomberg, adding that “mRNA vaccines have potential that needs to be carefully evaluated.”
What Are the Implications for Moderna and the Future of mRNA Vaccines?
The FDA’s decision has significant implications for Moderna and the broader mRNA vaccine landscape. While mRNA-1010 faces regulatory hurdles in the US, its acceptance for review in the European Union, Canada, and Australia highlights a divergence in regulatory perspectives. This could affect Moderna’s revenue projections and market strategy, particularly if the US market remains inaccessible. According to Moderna’s Q4 2025 financial results, the company anticipates significant revenue growth from its mRNA vaccine platform, but US regulatory approval is critical to achieving these targets. The outcome of Moderna’s discussions with the FDA will be closely watched by other companies developing mRNA vaccines, like Pfizer and BioNTech.
Beyond Moderna, the FDA’s stance could influence the development and regulatory pathways for other innovative vaccines. If the “best-available standard of care” requirement becomes a de facto benchmark, it may raise the bar for new vaccines to demonstrate superiority over existing options, potentially slowing down the introduction of novel technologies. This could affect the pace of innovation in the vaccine industry, particularly for vaccines targeting influenza and other infectious diseases. The World Health Organization (WHO) estimates that seasonal influenza causes 290,000 to 650,000 respiratory deaths globally each year, underscoring the importance of developing more effective vaccines. “The flu vaccine market is ripe for disruption,” says healthcare analyst Brian O’Malley from Cowen. “Moderna’s data showed promise, but regulatory uncertainty is always a risk.”
Products/Companies Mentioned
- Moderna – Biotechnology company specializing in mRNA therapeutics and vaccines, market cap of $60 billion, $19.3 billion revenue in 2025, lead product is mRNA-1273 (Spikevax) COVID-19 vaccine.
- mRNA-1010 – Moderna’s mRNA-based seasonal influenza vaccine candidate, currently under review in EU, Canada, and Australia.
- FDA (U.S. Food and Drug Administration) – US regulatory agency responsible for approving drugs, vaccines, and medical devices.
What This Means
- For consumers: The potential delay in availability of Moderna’s mRNA flu vaccine means that options for more effective flu protection might not be available as soon as anticipated.
- For investors: Moderna’s stock (MRNA) may experience volatility due to the regulatory uncertainty surrounding mRNA-1010’s approval in the US. Keep an eye on upcoming announcements from Moderna and the FDA after their meeting.
- For vaccine developers: The FDA’s decision highlights the increasing scrutiny and potential challenges in obtaining approval for innovative vaccines, particularly the requirements for demonstrating superiority over existing standards of care.
